Your browser is no longer supported. Please, upgrade your browser.
PACB Pacific Biosciences of California, Inc. daily Stock Chart
Pacific Biosciences of California, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own2.60% Shs Outstand153.45M Perf Week-0.67%
Market Cap592.62M Forward P/E- EPS next Y-0.61 Insider Trans-15.99% Shs Float148.77M Perf Month0.68%
Income-52.50M PEG- EPS next Q-0.18 Inst Own92.80% Short Float12.00% Perf Quarter28.10%
Sales90.10M P/S6.58 EPS this Y27.30% Inst Trans-0.02% Short Ratio13.78 Perf Half Y-20.02%
Book/sh0.39 P/B9.53 EPS next Y-15.10% ROA-30.10% Target Price5.33 Perf Year-37.35%
Cash/sh0.89 P/C4.16 EPS next 5Y30.00% ROE-86.80% 52W Range2.20 - 5.99 Perf YTD-27.72%
Dividend- P/FCF28.63 EPS past 5Y10.10% ROI-116.60% 52W High-35.07% Beta1.70
Dividend %- Quick Ratio1.20 Sales past 5Y8.40% Gross Margin41.00% 52W Low76.79% ATR0.23
Employees404 Current Ratio1.30 Sales Q/Q-4.90% Oper. Margin-56.80% RSI (14)57.45 Volatility4.67% 6.26%
OptionableYes Debt/Eq0.00 EPS Q/Q104.00% Profit Margin-58.30% Rel Volume0.58 Prev Close3.71
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout- Avg Volume1.30M Price3.89
Recom2.50 SMA206.60% SMA508.06% SMA200-7.45% Volume132,015 Change4.69%
Jun-02-20Resumed Cantor Fitzgerald Overweight $5
Mar-09-20Resumed Cantor Fitzgerald Overweight $5
Oct-15-19Upgrade Piper Jaffray Neutral → Overweight $8
Apr-02-19Downgrade Stephens Overweight → Equal-Weight $4.50 → $8
Oct-19-18Initiated Cowen Outperform
Nov-03-17Downgrade First Analysis Sec Overweight → Equal-Weight $4
Sep-28-17Downgrade CL King Buy → Neutral
Nov-03-16Reiterated Cantor Fitzgerald Buy $18 → $15
Jun-27-16Initiated CL King Buy
Apr-15-16Initiated First Analysis Sec Overweight $11
Feb-04-16Downgrade Piper Jaffray Overweight → Neutral
Jan-04-16Reiterated Cantor Fitzgerald Buy $11 → $18
Oct-23-15Upgrade Piper Jaffray Neutral → Overweight
Aug-27-15Initiated Cantor Fitzgerald Buy
Feb-04-15Reiterated Maxim Group Buy $10 → $11
Sep-26-13Reiterated Maxim Group Buy $4 → $8
Jan-14-13Reiterated Maxim Group Buy $3 → $4
Apr-19-11Initiated William Blair Mkt Perform
Mar-17-11Initiated Oppenheimer Perform $15
Dec-06-10Initiated Deutsche Bank Buy $18
Jun-23-20 01:21PM  
Jun-10-20 08:59AM  
Jun-08-20 04:02PM  
Jun-05-20 11:31AM  
May-17-20 06:01PM  
May-08-20 07:57AM  
May-07-20 11:30AM  
May-06-20 04:03PM  
Apr-30-20 10:30AM  
Apr-29-20 12:34PM  
Apr-27-20 01:09PM  
Apr-24-20 12:30PM  
Apr-21-20 07:22AM  
Apr-20-20 07:00AM  
Apr-08-20 07:30AM  
Mar-18-20 01:52PM  
Mar-07-20 11:31AM  
Mar-05-20 06:00PM  
Feb-25-20 05:40PM  
Feb-11-20 10:22AM  
Feb-08-20 06:53PM  
Feb-07-20 04:03PM  
Feb-06-20 06:25PM  
Jan-30-20 12:31PM  
Jan-27-20 05:21AM  
Jan-21-20 02:16PM  
Jan-03-20 03:34PM  
Jan-02-20 11:58PM  
Dec-30-19 08:31AM  
Dec-18-19 10:05AM  
Dec-07-19 12:26PM  
Nov-25-19 08:01AM  
Nov-20-19 08:39AM  
Nov-07-19 06:55PM  
Oct-31-19 10:34AM  
Oct-28-19 12:39PM  
Oct-10-19 07:30AM  
Sep-18-19 09:59AM  
Sep-05-19 09:31AM  
Sep-04-19 07:00AM  
Aug-09-19 08:54AM  
Aug-06-19 06:35PM  
Jul-25-19 10:33AM  
Jul-22-19 10:06AM  
Jul-19-19 04:34PM  
Jul-04-19 06:09PM  
Jun-21-19 10:42AM  
Jun-19-19 09:31PM  
Jun-18-19 10:09AM  
Jun-13-19 07:30AM  
Jun-02-19 09:30AM  
May-07-19 08:01AM  
May-03-19 04:01PM  
May-02-19 04:17PM  
Apr-24-19 10:33AM  
Apr-23-19 12:14PM  
Apr-20-19 02:00PM  
Apr-02-19 07:30AM  
Mar-13-19 09:30AM  
Feb-26-19 07:30AM  
Feb-18-19 05:53PM  
Feb-12-19 10:01AM  
Feb-11-19 06:20PM  
Feb-03-19 09:00AM  
Jan-31-19 10:31AM  
Jan-17-19 07:40AM  
Jan-04-19 08:27AM  
Dec-31-18 10:51AM  
Dec-18-18 03:40PM  
Dec-12-18 11:55PM  
Dec-10-18 05:06PM  
Dec-07-18 02:04PM  
Dec-06-18 09:39PM  
Nov-16-18 08:35AM  
Nov-15-18 10:02AM  
Nov-14-18 02:26PM  
Nov-12-18 07:05AM  
Nov-08-18 04:55PM  
Nov-07-18 10:09AM  
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes.The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and exonucleases. In addition, it provides binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprises reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Phillips James MichaelSVP, Research & DevelopmentMar 24Sale3.052,7608,421249,220Mar 24 06:12 PM
Phillips James MichaelSVP, Research & DevelopmentFeb 20Sale4.485,05022,624251,980Feb 24 05:55 PM
Hunkapiller MichaelChairman, CEO & PresidentFeb 20Sale4.50166,575749,7541,868,395Feb 24 04:15 PM
BARNES SUSAN KEVP, CFO and PAOFeb 19Sale4.4412,55855,758874,812Feb 25 07:09 PM
Hunkapiller MichaelChairman, CEO & PresidentFeb 19Sale4.4976,281342,3492,034,970Feb 20 05:33 PM
Hunkapiller MichaelChairman, CEO & PresidentFeb 18Sale4.49525,9952,363,2962,111,251Feb 20 05:33 PM